Oncolytics Biotech Inc T.ONC

OT:Cancer Radiopharmaceutical Therapy reports Adverse Events

[Noteable]

May 24, 1014 - J&J reports 4 patient deaths in early stage prostate cancer. Four patients died in Johnson & Johnson's Phase I study for its investigational targeted radiopharmaceutical candidate JNJ-6420 in metastatic castration-resistant prostate cancer, according to a readout released Thursday, ahead of next week's ASCO 2024 annual meeting. 

Thursday’s data come from 57 patients who had received at least one dose of JNJ-6420, of whom 31 stayed on treatment for 24 weeks or longer. 

However, in terms of safety, J&J’s investigational radiotherapy appears to be fairly toxic. More than 60% of patients developed treatment-emergent adverse events (TEAE) that were at least grade 3 in severity, while almost 37% had a serious TEAE.Common adverse events included anemia, low platelet count and abnormal reductions in white blood cells. 

Nine patients dropped out of the study due to severe side effects that were deemed related to the study drug.

 

https://www.biospace.com/article/asco24-j-and-j-reports-four-patient-deaths-in-early-stage-radiotherapy-prostate-cancer-trial/